The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study

Publication date: Available online 8 May 2019Source: The Lancet HaematologyAuthor(s): Daniel A Mulrooney, Geehong Hyun, Kirsten K Ness, Nickhill Bhakta, Ching-Hon Pui, Matthew J Ehrhardt, Kevin R Krull, Deborah B Crom, Wassim Chemaitilly, Deokumar K Srivastava, Mary V Relling, Sima Jeha, Daniel M Green, Yutaka Yasui, Leslie L Robison, Melissa M HudsonSummaryBackgroundTreatment for childhood acute lymphoblastic leukemia has evolved over the past five decades, with moderation of traditional chemotherapy and radiotherapy and the introduction of targeted immune-based and cellular-based therapies. The affect of these changes on late health outcomes has not been assessed. Using data from the The St Jude Lifetime (SJLIFE) Cohort, we aimed to characterise the magnitude of morbidity and patterns of late health outcomes among survivors of childhood acute lymphoblastic leukaemia treated over time.MethodsThe St Jude Lifetime (SJLIFE) Cohort is a retrospective cohort study with prospective follow-up and ongoing data accrual designed to facilitate longitudinal, clinically-based assessment of health outcomes among survivors of paediatric malignancies. 980 survivors included in this analysis were diagnosed with paediatric acute lymphoblastic leukaemia at St Jude Children's Research Hospital (SJCRH) between Aug 28, 1963, and July 19, 2003, were aged 18 years old and older at enrolment, had a minimum follow-up of 10 years after diagnosis, and completed an initial on-campus SJLIFE assessment as...
Source: The Lancet Haematology - Category: Hematology Source Type: research